Frequency and patterns of first- and second-line drug resistance-conferring mutations in Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in a cross-sectional study in Tigray Region, Ethiopia

World Health Organization (WHO), 2018 Coll, 2015, Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences, Genome Med, 7, 51, 10.1186/s13073-015-0164-0 Brhane, 2017, Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia, Infect Drug Resist, 10, 75, 10.2147/IDR.S127903 Tracevska, 2002, Mutations in the rpoB and katG genes leading to drug resistance in Mycobacterium tuberculosis in Latvia, J Clin Microbiol, 40, 3789, 10.1128/JCM.40.10.3789-3792.2002 Vidyaraj, 2017, Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes, J Epidemiol Glob Health, 7, 289, 10.1016/j.jegh.2017.09.002 Sharma, 2014, Rapid detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis using Genotype MTBDRplus assay in Nepal, Int Sch Res Notices, 2014 Biadglegne, 2013, Magnitude of gene mutations conferring drug resistance in Mycobacterium tuberculosis isolates from lymph node aspirates in Ethiopia, Int J Med Sci, 10, 1589, 10.7150/ijms.6806 Alelign, 2019, Molecular detection of Mycobacterium tuberculosis sensitivity to rifampicin and isoniazid in South Gondar Zone, Northwest Ethiopia, BMC Infect Dis, 19, 343, 10.1186/s12879-019-3978-3 Gagneux, 2006, Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis, PLoS Pathog, 2, e61, 10.1371/journal.ppat.0020061 Tadesse, 2016, Drug resistance-conferring mutations in Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia, Int J Mycobacteriol, 5, 185, 10.1016/j.ijmyco.2016.02.009 Federal Democratic Republic of Ethiopia Central Statistical Agency, 2017 Ministry of Health of Ethiopia, 2016 World Health Organization (WHO), 2014 Kent, 1985 Hain Lifescience, 2015 Abate, 2014, Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment, Addis Ababa, Ethiopia, Int J Tuberc Lung Dis, 18, 946, 10.5588/ijtld.13.0926 Minh, 2012, Molecular characteristics of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Vietnam, J Clin Microbiol, 50, 598, 10.1128/JCM.05171-11 Jou, 2005, Genetic diversity of multidrug-resistant Mycobacterium tuberculosis isolates and identification of 11 novel rpoB alleles in Taiwan, J Clin Microbiol, 43, 1390, 10.1128/JCM.43.3.1390-1394.2005 Polu, 2019, Analysis of drug resistance mutations in pulmonary Mycobacterium tuberculosis isolates in the Southern coastal region of Andhra Pradesh, India, Braz J Infect Dis, 23, 281, 10.1016/j.bjid.2019.07.002 Damena, 2019, Genetic diversity and drug susceptibility profiles of Mycobacterium tuberculosis obtained from Saint Peter’s TB Specialized Hospital, Ethiopia, PLoS One, 14, 10.1371/journal.pone.0218545 Cavusoglu, 2002, Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay, J Clin Microbiol, 40, 4435, 10.1128/JCM.40.12.4435-4438.2002 Aktas, 2005, Molecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkey, Microb Drug Resist, 11, 94, 10.1089/mdr.2005.11.94 Somoskovi, 2001, The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis, Respir Res, 2, 164, 10.1186/rr54 Maharjan, 2018, Genetic diversity and distribution dynamics of multidrug-resistant Mycobacterium tuberculosis isolates in Nepal, Sci Rep, 8, 10.1038/s41598-018-34306-w Zaw, 2018, Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis, J Infect Public Health, 11, 605, 10.1016/j.jiph.2018.04.005 Bostanabad, 2008, Detection of mutation in isoniazid-resistant Mycobacterium tuberculosis isolates from tuberculosis patients in Belarus, Indian J Med Microbiol, 26, 143 Oudghiri, 2018, Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco, BMC Infect Dis, 18, 98, 10.1186/s12879-018-3009-9 Muthaiah, 2017, Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates, J Clin Tuberc Other Mycobact Dis, 8, 19, 10.1016/j.jctube.2017.06.001 Isakova, 2018, Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic, BMC Microbiol, 18, 22, 10.1186/s12866-018-1168-x Seifert, 2015, Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review, PLoS One, 10, 10.1371/journal.pone.0119628 Cao, 2020, Genotypic characterization of katG, inhA, and ahpC in isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Shanghai, China, Jundishapur J Microbiol, 10.5812/jjm.95713 Ando, 2010, Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis, Antimicrob Agents Chemother, 54, 1793, 10.1128/AAC.01691-09 Pym, 2002, Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans, Infect Immun, 70, 4955, 10.1128/IAI.70.9.4955-4960.2002 Fenner, 2012, Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis, Antimicrob Agents Chemother, 56, 3047, 10.1128/AAC.06460-11 Nuru, 2015, Genetic diversity of Mycobacterium tuberculosis complex isolated from tuberculosis patients in Bahir Dar City and its surroundings, Northwest Ethiopia, Biomed Res Int, 2015, 10.1155/2015/174732 Gardee, 2017, Evaluation of the GenoType MTBDRsl version 2.0 assay for second-line drug resistance detection of Mycobacterium tuberculosis isolates in South Africa, J Clin Microbiol, 55, 791, 10.1128/JCM.01865-16 Li, 2019, Mutation and transmission profiles of second-line drug resistance in clinical isolates of drug-resistant Mycobacterium tuberculosis from Hebei Province, China, Front Microbiol, 10, 1838, 10.3389/fmicb.2019.01838 Li, 2014, Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis, Emerg Microbes Infect, 3, e19, 10.1038/emi.2014.21 Mogashoa, 2019, Detection of second line drug resistance among drug resistant Mycobacterium tuberculosis isolates in Botswana, Pathogens, 8, 208, 10.3390/pathogens8040208 Avalos, 2015, Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review, PLoS One, 10, 10.1371/journal.pone.0120470